Pipeline
Next-Generation Obesity Drug Pipeline
The competitive landscape retatrutide will enter: incretin, amylin and multi-receptor candidates in late-stage development, tracked by phase and latest movement.
Pipeline
Pipeline tracker
The competitive set of incretin, amylin and multi-receptor candidates in late-stage obesity development.
| Drug | Developer | Mechanism | Administration | Phase | Primary Indication |
|---|---|---|---|---|---|
| Retatrutide (LY3437943) | Eli Lilly and Company | GLP-1 / GIP / Glucagon | Weekly subcutaneous | Phase 3 | Obesity |
| CagriSema | Novo Nordisk | Amylin + GLP-1 | Weekly subcutaneous | Phase 3 | Obesity |
| Orforglipron | Eli Lilly and Company | Oral GLP-1 (non-peptide) | Daily oral | Phase 3 | Obesity, type 2 diabetes |
| MariTide | Amgen | GIP antagonist / GLP-1 agonist | Monthly subcutaneous | Phase 3 | Obesity |
| Amycretin | Novo Nordisk | Amylin + GLP-1 | Subcutaneous / oral | Phase 2 | Obesity |
| Survodutide | Boehringer Ingelheim / Zealand | GLP-1 / Glucagon | Weekly subcutaneous | Phase 3 | Obesity, MASH |
| Petrelintide | Zealand Pharma / Roche | Amylin analogue | Weekly subcutaneous | Phase 2 | Obesity |
Weekly Briefing
The Retatrutide Report
The most important retatrutide developments, once a week.
- Clinical trial changes
- New PubMed research
- FDA / EMA regulatory developments
- Eli Lilly announcements
- Major efficacy and safety updates
No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.